Robert Fried Biography and Net Worth

CEO of Niagen Bioscience

Robert Fried is the Chief Executive Officer (CEO) of ChromaDex. Mr. Fried is an Academy Award and Emmy Award winning motion picture producer. He has held senior roles at entertainment companies Savoy Pictures (CEO), Columbia Pictures (Executive Vice President) and Fried Films (founder, CEO). He has also founded and served as CEO of internet companies Feeln (now Hallmark Movies Now), WHN (a leading e-commerce service provider), and Healthspan Research (now part of ChromaDex). Mr. Fried holds a B.S. from Cornell University and a M.B.A. from the Columbia University Graduate School of Business.

What is Robert N. Fried's net worth?: The estimated net worth of Robert N. Fried is at least $631.76 thousand as of May 31st, 2023. Mr. Fried owns 95,001 shares of Niagen Bioscience stock worth more than $631,757 as of December 4th. This net worth estimate does not reflect any other investments that Mr. Fried may own. Learn More about Robert N. Fried's net worth.
How do I contact Robert N. Fried?: The corporate mailing address for Mr. Fried and other Niagen Bioscience executives is 10900 WILSHIRE BLVD, SUITE 600, LOS ANGELES, CA, 90024. Niagen Bioscience can also be reached via phone at (310) 388-6706 and via email at [email protected]. Learn More on Robert N. Fried's contact information.
Has Robert N. Fried been buying or selling shares of Niagen Bioscience?: Robert N. Fried has not been actively trading shares of Niagen Bioscience during the last quarter. Most recently, on Wednesday, May 31st, Robert N. Fried bought 7,000 shares of Niagen Bioscience stock. The stock was acquired at an average cost of $1.42 per share, with a total value of $9,940.00. Following the completion of the transaction, the chief executive officer now directly owns 95,001 shares of the company's stock, valued at $134,901.42. Learn More on Robert N. Fried's trading history.
Who are Niagen Bioscience's active insiders?: Niagen Bioscience's insider roster includes Stephen Block (Director), Robert Fried (CEO), Frank Jaksch, Jr. (Director), Ozan Pamir (CFO), and Kristin Patrick (Director). Learn More on Niagen Bioscience's active insiders.
Are insiders buying or selling shares of Niagen Bioscience?: In the last twelve months, Niagen Bioscience insiders bought shares 2 times. They purchased a total of 6,685 shares worth more than $45,613.65. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 37,161 shares worth more than $230,026.59. The most recent insider tranaction occured on November, 14th when CFO Ozan Pamir bought 4,465 shares worth more than $30,406.65. Insiders at Niagen Bioscience own 9.4% of the company. Learn More about insider trades at Niagen Bioscience.
Information on this page was last updated on 11/14/2025.

Robert N. Fried Insider Trading History at Niagen Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/31/2023	Buy	7,000	$1.42	$9,940.00	95,001
9/30/2022	Buy	80,000	$1.25	$100,000.00	972,314
3/16/2022	Buy	25,000	$2.16	$54,000.00
5/13/2021	Buy	10,000	$6.65	$66,500.00	882,561
5/19/2020	Buy	1,000	$4.55	$4,550.00
11/14/2019	Buy	10,000	$3.20	$32,000.00
8/23/2019	Buy	2,500	$4.03	$10,075.00
5/21/2019	Buy	2,253	$4.43	$9,980.79
3/15/2019	Buy	5,000	$3.80	$19,000.00
5/15/2018	Buy	10,000	$3.63	$36,300.00
8/15/2017	Buy	10,000	$3.15	$31,500.00	583,241
9/1/2016	Buy	15,000	$3.39	$50,850.00	66,979

Robert N. Fried Buying and Selling Activity at Niagen Bioscience

Niagen Bioscience Company Overview

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Today's Range

Now: $6.70

$6.51

$6.71

50 Day Range

MA: $7.28

$6.40

$9.90

2 Week Range

Now: $6.70

$5.16

$14.69

Volume

581,224 shs

Average Volume

833,772 shs

Market Capitalization

$534.73 million

P/E Ratio

27.92

Dividend Yield

N/A

Beta

2.31